MEOI and HRQoL in CLL Patients Treated With BTKis
NCT04938141 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 23
Last updated 2025-05-21
Summary
This is a multi-site observational study of medical events of interest (MEOI) and health-related quality of life (HRQoL) in chronic lymphocytic leukemia (CLL) patients initiating treatment with the Bruton's tyrosine kinase inhibitors (BTKi) acalabrutinib or ibrutinib in the United States (US)
Conditions
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-10-07
- Primary Completion
- 2024-09-26
- Completion
- 2024-09-26
Countries
- United States
Study Locations
More Related Trials
-
Ibrutinib in Previously Untreated Binet Stage a Chronic Lymphocytic Leukemia with Risk of Disease Progression
NCT02863718 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT02556892 ·Status: COMPLETED ·Phase: PHASE1
-
Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.
NCT02315768 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL
NCT01722487 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice
NCT03425591 ·Status: COMPLETED
-
A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
NCT04694560 ·Status: WITHDRAWN
-
A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
NCT02717611 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL
NCT03980002 ·Status: RECRUITING ·Phase: PHASE2
-
REfractorinesS to Ibrutinib BTKi and Systemic Targeted Therapy
NCT05621148 ·Status: COMPLETED
-
Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom
NCT05557695 ·Status: RECRUITING
-
Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies
NCT03932331 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
NCT06651970 ·Status: RECRUITING ·Phase: PHASE4
-
Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT06757647 ·Status: RECRUITING ·Phase: PHASE2
-
Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant
NCT03267186 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
NCT05963074 ·Status: RECRUITING ·Phase: PHASE2
-
A Study to Assess Change in Functioning and Health Related Quality of Life in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Treatments in Routine Clinical Practice in Spain
NCT06125795 ·Status: ACTIVE_NOT_RECRUITING
-
Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy
NCT02381080 ·Status: COMPLETED ·Phase: PHASE1
-
Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia
NCT00281918 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate Impact of Ibrutinib on the Quality of Life (QOL) in Patients With Chronic Lymphocytic Leukemia
NCT04016636 ·Status: COMPLETED
-
Real-World Disease Management and Outcomes in Chronic Myeloid Leukaemia
NCT05893836 ·Status: COMPLETED
-
A Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Participants With B Cell Malignancy
NCT03301207 ·Status: COMPLETED ·Phase: PHASE1
-
Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
NCT02129062 ·Status: TERMINATED ·Phase: PHASE2
-
Observational Study of CLL/SLL Treatment and Ibrutinib Treatment of CLL/SLL in Routine Clinical Practice
NCT04094051 ·Status: UNKNOWN
-
Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Chronic Lymphocytic Leukemia
NCT04178798 ·Status: COMPLETED ·Phase: PHASE3
-
Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous Leukemia
NCT00053144 ·Status: COMPLETED ·Phase: PHASE1